BioCentury
ARTICLE | Distillery Therapeutics

Cancer

December 19, 2018 8:48 PM UTC

Mouse studies suggest the HDAC inhibitor entinostat alone or in combination with chemotherapy could help treat alveolar rhabdomyosarcoma. In an orthotopic mouse model of alveolar rhabdomyosarcoma, entinostat decreased tumor growth compared with vehicle, and entinostat plus the chemotherapy vincristine decreased tumor growth compared with vehicle or either agent alone. In seven patient-derived xenograft (PDX) mouse models of alveolar rhabdomyosarcoma, entinostat plus vincristine decreased tumor growth. In three of the PDX models, entinostat alone decreased tumor growth compared with vehicle. Next steps include testing entinostat in models of other rhabdomyosarcoma subtypes.

Bayer AG, EOC Pharma Group, Kyowa Hakko Kirin Co. Ltd., NovaMedica LLC and Syndax Pharmaceuticals Inc. have entinostat (KHK2375, SNDX-275, ms-275) in Phase II testing to treat breast cancer, acute myelogenous leukemia (AML) and non-small cell lung cancer (NSCLC) and in Phase I/II testing to treat colorectal cancer, melanoma, ovarian cancer and renal cancer...